STOCK TITAN

Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference

Carisma Therapeutics Inc. (Nasdaq: CARM) is set to participate in The Citizens JMP Life Sciences Conference.

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Rhea-AI Summary

Carisma Therapeutics Inc. (Nasdaq: CARM) is set to participate in The Citizens JMP Life Sciences Conference. The company, a clinical-stage biopharmaceutical firm specializing in innovative immunotherapies, will have its President and CEO, Steven Kelly, engage in a fireside chat on May 13th at 12:00 pm ET. The event will be webcasted and archived on the Investor Relations webpage.

Loading...
Loading translation...
Argus Session date unavailable
-1.54% session move Open Argus
Details

News Market Reaction – CARM

The recorded move for CARM in the trading session of this news was -1.54%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

PHILADELPHIA, May 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in a fireside chat at The Citizens JMP Life Sciences Conference on Monday, May 13th at 12:00 pm ET.

An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limited time following the event.

About Carisma

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.carismatx.com.

Investors:
Shveta Dighe
Head of Investor Relations
investors@carismatx.com

Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-participate-in-the-citizens-jmp-life-sciences-conference-302135910.html

SOURCE Carisma Therapeutics Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Carisma Therapeutics participate in The Citizens JMP Life Sciences Conference?

Carisma Therapeutics will participate in The Citizens JMP Life Sciences Conference on Monday, May 13th at 12:00 pm ET.

Who will represent Carisma Therapeutics at the conference?

Steven Kelly, the President and Chief Executive Officer of Carisma Therapeutics, will engage in a fireside chat at the conference.

Where can I access the audio webcast of the event?

The audio webcast of the event will be available on Carisma Therapeutics' Investor Events section of the Investor Relations webpage.

Keep reading